ALSUntangled No. 34: GM604.

Gary L. Pattee | R. Conwit | J. Licht | P. Andersen | J. Glass | O. Hardiman | M. Benatar | S. Perrin | P. Wicks | J. Heywood | J. Rothstein | M. Bromberg | V. Drory | R. Bowser | J. Shefner | P. Barkhaus | Robert G. Miller | E. Pioro | M. Strong | L. Zinman | L. Gutmann | J. Kissel | Kristiana Salmon | K. Sharma | C. Jackson | L. Rowland | C. Karam | R. Bedlack | G. Pattee | C. Shoesmith | D. Forshew | J. Rosenfeld | S. Nash | M. Weiss | B. Morrison | T. Heiman-Patterson | S. Sathornsumetee | E. Kabashi | T. Bertorini | C. Armon | M. Ogino | N. Lechtzin | N. Maragakis | F. Vieira | N. Zach | J. Robertson | J. Ravits | M. Dimachkie | N. Atassi | A. Sherman | Melanie L Leitner | L. Ostrow | M. Polak | R. Tandan | D. Saperstein | J. Caress | E. Sorenson | T. Levine | Kate Dalton | T. Mozaffar | K. Boylan | J. Russell | D. Macgowan | G. Sachs | B. Oskarsson | Daniel M. Pastula | Larry Phillips | D. Moore | S. Rudnicki | C. Quinn | Michael H. Rivner | R. Goldstein | J. Wymer | A. Ghavanini | L. McClusky | Pamela Kittrell | Jonathan M. Goldstein | Gregory T. Carter | Josep Gamez | Yunxia Wang | S. Novella | Lisa Kinsley | K. Mitchell | Jon Baker | K. Tindall | Ginna Gonzalez | M. Grosso | C. Lomen‐Hoerth | Eric Valor | B. Gerecke | A. Verma | S. Kolb | Muddasir Quereshi | G. Levitsky | E. Carmi | Yvonne Baker | Jeff Dietz | C. Oster | Christina N. Fournier | Eric N. Valor | J. Baker | Steven P Novella | Daniel M. Pastula | Steven M. Nash | C. lomen-Hoerth | Kathy Mitchell | Katherine Tindall | Craig D. Oster

[1]  Paul Wicks,et al.  How common are ALS plateaus and reversals? , 2016, Neurology.

[2]  M. Cudkowicz,et al.  The PRO-ACT database , 2014, Neurology.

[3]  Brian A. Nosek,et al.  Power failure: why small sample size undermines the reliability of neuroscience , 2013, Nature Reviews Neuroscience.

[4]  V. Gribkoff,et al.  The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis , 2011, Nature Medicine.

[5]  R. Bedlack,et al.  Historical controls in ALS trials , 2011, Neurology.

[6]  S. Paganoni,et al.  Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis , 2011, Muscle & nerve.

[7]  Albert C. Ludolph,et al.  Guidelines for preclinical animal research in ALS/MND: A consensus meeting , 2010, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[8]  E. Beghi,et al.  Prognostic factors in ALS: A critical review , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[9]  W. Bamlet,et al.  Subcutaneous IGF-1 is not beneficial in 2-year ALS trial , 2008, Neurology.

[10]  M. Kindy,et al.  Motoneuronotrophic factor analog GM6 reduces infarct volume and behavioral deficits following transient ischemia in the mouse , 2008, Brain Research.

[11]  Gabriele Siciliano,et al.  Lithium delays progression of amyotrophic lateral sclerosis , 2008, Proceedings of the National Academy of Sciences.

[12]  Farrah J Mateen,et al.  Strength, physical activity, and fasciculations in patients with ALS , 2008, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[13]  M. Benatar.  Lost in translation: Treatment trials in the SOD1 mouse and in human ALS , 2007, Neurobiology of Disease.

[14]  Richard Smith,et al.  Peer Review: A Flawed Process at the Heart of Science and Journals , 2006, Journal of the Royal Society of Medicine.

[15]  J. Ioannidis,et al.  Why Most Published Research Findings Are False , 2005, PLoS medicine.

[16]  R Stephen Berry,et al.  Validity and Ethics in Science , 2003, Science.

[17]  D. Arnold,et al.  A prospective, randomized, placebo‐controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: feasibility and results , 2003, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[18]  M. Swash,et al.  Consensus guidelines for the design and implementation of clinical trials in ALS , 1999, Journal of the Neurological Sciences.